DNA (Double Strand) Antibody By IFA - Reflex end point titre, Serum

DNA (Double-Strand) Antibody by IFA – Reflex End Point Titre, Serum

Test Overview

Anti-double-stranded DNA (anti-dsDNA) antibody testing detects autoantibodies directed against double-stranded DNA. The test is commonly used as an important serological marker in the evaluation and monitoring of systemic lupus erythematosus (SLE) and other autoimmune disorders.

Method

Indirect Immunofluorescence Assay (IFA) with reflex end-point titre determination for positive samples.

Clinical Indications

• Evaluation of suspected SLE
• Investigation of autoimmune symptoms such as unexplained joint pain, rashes, or systemic inflammation
• Supporting the diagnosis of SLE along with clinical findings and other autoimmune markers
• Monitoring disease activity, particularly in patients with established SLE
• Evaluation of suspected lupus nephritis in appropriate clinical settings

Sample

Serum

Test Interpretation

• Negative: Anti-dsDNA antibodies are not detected at the tested dilution.
• Positive: Anti-dsDNA antibodies are detected; the end-point titre provides an estimate of antibody level.
• Higher antibody titres may be associated with SLE and, in some patients, increased disease activity, particularly renal involvement.

Important: Results should always be interpreted together with clinical findings and other laboratory investigations. A negative result does not completely exclude SLE.

Key Benefits

• Detects disease-associated anti-dsDNA autoantibodies
• Provides a reflex end-point titre when positive
• Supports autoimmune disease evaluation
• Useful as part of a comprehensive SLE work-up

Related Tests

ANA by IFA, ANA Profile, ENA Profile, Complement C3 & C4, Anti-Sm Antibody, Urine Routine/Microscopy and renal function tests may be considered based on clinical indications.